Chengdu Ucello Biotechnology

Chengdu Ucello Biotechnology is a clinical-stage biotechnology company headquartered in Chengdu, China, dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies. The company utilizes its proprietary C-U (Common-Universal) platform to engineer cell products that address the high cost and manufacturing complexities associated with traditional autologous CAR-T treatments. Its lead program, UC101, is a CD19-targeted allogeneic CAR-T therapy currently in clinical development for relapsed or refractory B-cell hematologic malignancies. Ucello's integrated approach encompasses discovery, gene editing, and large-scale GMP manufacturing to improve patient access to transformative immunotherapies. The company has successfully secured significant venture capital funding from prominent investors like Matrix Partners China and Lapam Capital to advance its pipeline. By focusing on allogeneic solutions, Ucello aims to provide immediate treatment options for patients with aggressive cancers who cannot wait for autologous manufacturing.